Update: Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial
(Updates with the latest stock move in the headline and in the first paragraph.)Rezolute (RZLT) shares rose about 16% in Tuesday afternoon trading after the company said that six of eight participants enrolled in a phase 3 trial of ersodetug in uncontrolled hypoglycemia caused by tumor hyperinsulinism have already met the responder criterion for the study's primary endpoint.The primary endpoint of the study, which aims to enroll 16 patients with insulinoma or non-islet cell tumors, is the number of participants achieving at least a 50% reduction from baseline in intravenous glucose requirements within the 8-week pivotal treatment phase, the company said.Rezolute said ersodetug has been well-tolerated in the pivotal and extension phases of the study, with no drug-related adverse events or other safety findings reported to date.Topline results for the fully enrolled open-label phase 3 study are expected in H2, Rezolute said.Price: $4.18, Change: $+0.57, Percent Change: +15.65%
